Lixte Biotechnology Holdings Balance Sheet Health
Financial Health criteria checks 4/6
Lixte Biotechnology Holdings has a total shareholder equity of $2.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.7M and $421.5K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.60m |
| Equity | US$2.25m |
| Total liabilities | US$421.47k |
| Total assets | US$2.67m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 8640's short term assets ($2.7M) exceed its short term liabilities ($421.5K).
Long Term Liabilities: 8640 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 8640 is debt free.
Reducing Debt: 8640 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8640 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 8640 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.5% each year